Student or educator? Sign up with your school email and get 6 months of Pro free.

The DOI matches its Crossref record; 65 of the 65 references it cites were found in a registry or an index; 55 of the 94 sources its claims cite were checked for support.

Structural mechanism for inhibition of PP2A-B56α and oncogenicity by CIP2A

Open access

Abstract

The protein phosphatase 2A (PP2A) heterotrimer PP2A-B56α is a human tumour suppressor. However, the molecular mechanisms inhibiting PP2A-B56α in cancer are poorly understood. Here, we report molecular level details and structural mechanisms of PP2A-B56α inhibition by an oncoprotein CIP2A. Upon direct binding to PP2A-B56α trimer, CIP2A displaces the PP2A-A subunit and thereby hijacks both the B56α, and the catalytic PP2Ac subunit to form a CIP2A-B56α-PP2Ac pseudotrimer. Further, CIP2A competes with B56α substrate binding by blocking the LxxIxE-motif substrate binding pocket on B56α. Relevant to oncogenic activity of CIP2A across human cancers, the N-terminal head domain-mediated interaction with B56α stabilizes CIP2A protein. Functionally, CRISPR/Cas9-mediated single amino acid mutagenesis of the head domain blunted MYC expression and MEK phosphorylation, and abrogated triple-negative breast cancer in vivo tumour growth. Collectively, we discover a unique multi-step hijack and mute protein complex regulation mechanism resulting in tumour suppressor PP2A-B56α inhibition. Further, the results unfold a structural determinant for the oncogenic activity of CIP2A, potentially facilitating therapeutic modulation of CIP2A in cancer and other diseases.

Overview

CoChat Summary

TL;DR

CIP2A inhibits the tumour suppressor PP2A-B56α by binding the B56α N-terminal head domain, displacing PP2A-A to form a CIP2A-B56α-PP2Ac pseudotrimer, and sterically blocking B56α LxxIxE-motif substrate binding. A single K21A mutation in the CIP2A head domain destabilizes CIP2A, disrupts CIP2A-B56α interaction, and abrogates triple-negative breast cancer growth in vitro and in vivo.

Key findings

  • CIP2A binds B56α primarily through its N-terminal head domain, displaces the PP2A-A subunit from the PP2A-B56α trimer, and forms a CIP2A-B56α-PP2Ac pseudotrimer; it also blocks the B56α LxxIxE-motif substrate pocket, out-competing BubR1 from B56α.
  • Head-domain mutations affect full-length CIP2A protein levels: K8A “practically abolished” expression, K21A and K40A significantly inhibited it, and A24E increased it; K647A rescued K8A expression, linking stability to C-terminal ubiquitination.
  • CRISPR/Cas9 K21A mutant MDA-MB-231 clones showed almost complete loss of CIP2A-B56α interaction by PLA, were “almost completely incompetent” to grow on soft agar, and in orthotopic xenografts clone 1 produced only 5/8 palpable tumours with mean volume 113 mm³ after 30 days.
  • AP-MS showed CIP2A overexpression decreased B56α association with PPP2R1A and, among significantly affected B56α interactors, 80% had decreased B56α binding and 63% had a candidate LxxIxE motif; phosphoproteomics found 78 phosphopeptides from 63 proteins downregulated in K21A cells, with 53% containing a candidate LxxIxE motif and an additional 15% being interactors of such proteins (68% total).

Methods

  • Multidisciplinary structural and biochemical approach: chemical cross-linking coupled to mass spectrometry (XL-MS) with DSS and DMTMM, GST pull-down assays, size-exclusion chromatography, and in vitro competition assays using recombinant CIP2A fragments, B56α, PP2Ac, and BubR1(647-720).
  • Cell-based validation used 22RV1 prostate cancer cells, MDA-MB-231 triple-negative breast cancer cells, HEK-293-T cells, and murine NIH3T3 cells; CRISPR/Cas9 with two gRNAs generated MDA-MB-231 CIP2A K21A single-cell clones, compared with RNP-transfected controls.
  • Proteomic analyses included affinity purification coupled to MS (AP-MS) of B56α interactome in NIH3T3 cells and TMT-based phosphoproteomics of MDA-MB-231 control versus CIP2A K21A clone 1; in vivo tumour growth used orthotopic mammary fat pad xenografts in athymic nude mice (control n=7, K21A clone1 n=8, K21A clone2 n=8).

Limitations

  • The paper states that XL-MS should be considered a screening experiment whose results need further experimental validation, and that the XL-MS data may contain cross-links that are not functionally relevant.
  • The paper states that crystallization of the CIP2A-B56α complex has not been successful and that additional structural studies would be required to understand molecular-level details of CIP2A and NOCIVA interactions with PP2A-B56; it also notes that recombinant full-length CIP2A production remains elusive, so full-length studies relied on V5-tagged constructs in cells.
  • The paper states that the data do not exclude other potential mechanisms by which CIP2A promotes oncogenesis; evident from the text, some biochemical experiments had low replication (e.g., size-exclusion chromatography in Fig. 4E, F is labelled N=1), and several head-domain mutants could not be expressed as bacterial proteins due to instability.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1038/s41467-023-36693-9

Cites

65 of 65 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

Fig. 1 CIP2A interacts with B56α via its N-terminal head domain. A In red are indicated CIP2A(1-560) residues identified in inter-molecular cross-links to B56α using DSS and DMTMM cross-linkers. CIP2A 1-560 homodimer (PDB: 5UFL) monomers are shown either as ribbon or space filling models. In the space filling model 1-330 amino acids are in cyan including in purple the CIP2A head domain identified in this study. The 331-560 region including the dimerization domain is shown as turquoise. Due to high molecular flexibility of the N-terminal region of CIP2A, positions of residues K21 and E23 (indicated with*) had to be approximated using A24 position and K40 using position of R43. B Distribution of B56α (PDB: 6NTS) residues cross-linked to CIP2A by using DSS and DMTMM chemistries. Cross-linked amino acids are in red and roughly distributed to two distinct regions on B56α shown in two different B56α orientations. Insert shows the overall structural organization of PP2A-B56α trimer consisting of PP2A-A, PP2Ac, and B56α. C Overlap of the B56α cross-links identified for two different CIP2A fragments, 1-330 and 1-560. D Overlap of the CIP2A cross-links on B56α using CIP2A fragments, 1-330 and 1-560. D, E The indicated cross-link sites are combined from both the DSS and DMTMM experiments. E Zoom-into the CIP2A´s head domain, shown for one CIP2A monomer. CIP2A sites found in cross-links, with DSS and DMTMM, to B56α are in red, and the head domain (1-43 aa) is coloured in purple. Residue annotation is the same as in panel (A).
Fig. 1 CIP2A interacts with B56α via its N-terminal head domain. A In red are indicated CIP2A(1-560) residues identified in inter-molecular cross-links to B56α using DSS and DMTMM cross-linkers. CIP2A 1-560 homodimer (PDB: 5UFL) monomers are shown either as ribbon or space filling models. In the space filling model 1-330 amino acids are in cyan including in purple the CIP2A head domain identified in this study. The 331-560 region including the dimerization domain is shown as turquoise. Due to high molecular flexibility of the N-terminal region of CIP2A, positions of residues K21 and E23 (indicated with*) had to be approximated using A24 position and K40 using position of R43. B Distribution of B56α (PDB: 6NTS) residues cross-linked to CIP2A by using DSS and DMTMM chemistries. Cross-linked amino acids are in red and roughly distributed to two distinct regions on B56α shown in two different B56α orientations. Insert shows the overall structural organization of PP2A-B56α trimer consisting of PP2A-A, PP2Ac, and B56α. C Overlap of the B56α cross-links identified for two different CIP2A fragments, 1-330 and 1-560. D Overlap of the CIP2A cross-links on B56α using CIP2A fragments, 1-330 and 1-560. D, E The indicated cross-link sites are combined from both the DSS and DMTMM experiments. E Zoom-into the CIP2A´s head domain, shown for one CIP2A monomer. CIP2A sites found in cross-links, with DSS and DMTMM, to B56α are in red, and the head domain (1-43 aa) is coloured in purple. Residue annotation is the same as in panel (A).CC BY · PubMed Central
Fig. 2 The N-terminal head domain stabilizes CIP2A protein expression in cancer cells. A Mutations on the N-terminal head of CIP2A (PDB: 5UFL) are indicated with different colours used also in bar graphs B,E,G,I. B Transient over-expression of full-length CIP2A(1-905)V5 variants in prostate cancer 22RV1 cells. Representative Western blot images are shown in S5. Quantification is shown as a mean + S.E.M. from N = 3 biological repeats. Expression levels of CIP2A mutants were normalized to expression of WT CIP2A, which was set as value 1 in each experiment. Two-tailed One sample Wilcoxon t test. Source data are provided as a Source Data file. C Impact of cancer-derived CIP2A head domain mutants on CIP2A full length protein expression in breast cancer MDA-MB-231 cells. D, F GST pull-down assay comparing direct B56α interaction between recombinant GST-tagged CIP2A(1-560) WT protein and K8A or A24E mutants. Source data are provided as a Source Data file. E, G Quantification of the data from D and F. B56α signal from eluates were normalized to GST signal. Quantification is shown as a mean + S.E.M. from N = 4 and 3 biological repeats, respectively. B56α signal from mutants were normalized to signal from WT CIP2A, set as a value 1 in each experiment. E Two-tailed One sample Wilcoxon t test. H Analysis of combinatorial effects of stabilizing and destabilizing full-length CIP2A(1-905)V5 head mutants by transient over-expression in triple negative breast cancer MDA-MB-231 cells. Source data are provided as a Source Data file. I Quantification of (H). Shown is a mean + S.E.M. from N = 3 biological repeats. Expression levels of CIP2A mutants were normalized to expression of WT CIP2A set as value 1 in each experiment. Two-tailed One sample Wilcoxon t test.
Fig. 2 The N-terminal head domain stabilizes CIP2A protein expression in cancer cells. A Mutations on the N-terminal head of CIP2A (PDB: 5UFL) are indicated with different colours used also in bar graphs B,E,G,I. B Transient over-expression of full-length CIP2A(1-905)V5 variants in prostate cancer 22RV1 cells. Representative Western blot images are shown in S5. Quantification is shown as a mean + S.E.M. from N = 3 biological repeats. Expression levels of CIP2A mutants were normalized to expression of WT CIP2A, which was set as value 1 in each experiment. Two-tailed One sample Wilcoxon t test. Source data are provided as a Source Data file. C Impact of cancer-derived CIP2A head domain mutants on CIP2A full length protein expression in breast cancer MDA-MB-231 cells. D, F GST pull-down assay comparing direct B56α interaction between recombinant GST-tagged CIP2A(1-560) WT protein and K8A or A24E mutants. Source data are provided as a Source Data file. E, G Quantification of the data from D and F. B56α signal from eluates were normalized to GST signal. Quantification is shown as a mean + S.E.M. from N = 4 and 3 biological repeats, respectively. B56α signal from mutants were normalized to signal from WT CIP2A, set as a value 1 in each experiment. E Two-tailed One sample Wilcoxon t test. H Analysis of combinatorial effects of stabilizing and destabilizing full-length CIP2A(1-905)V5 head mutants by transient over-expression in triple negative breast cancer MDA-MB-231 cells. Source data are provided as a Source Data file. I Quantification of (H). Shown is a mean + S.E.M. from N = 3 biological repeats. Expression levels of CIP2A mutants were normalized to expression of WT CIP2A set as value 1 in each experiment. Two-tailed One sample Wilcoxon t test.CC BY · PubMed Central
Fig. 3 Single amino acid mutation on the N-terminal head domain of CIP2A abrogates TNBC tumorigenicity. A Western blot analysis of CIP2A and MYC protein expression in two independent MDA-MB-231 CIP2A K21A mutant clones. Source data are provided as a Source Data file. B Proximity ligation assay (PLA) for interaction between HA-B56α and endogenous CIP2A. MDA-MB-231-Control and MDA-MB-231_K21A mutant clone1 cells transfected with HA-B56α construct were subjected to PLA with anti-HA and anti-CIP2A antibodies. Red dot indicates the association between HA-B56α and endogenous CIP2A proteins. Shown is a representative image from N = 3 PLA experiments. Scale bar = 10 µm. C Quantification of PLA shown in (B) using automated macro detecting PLA signals. Error bar represent mean +/− SD from 3 different fields from 2 technical replicates. Two-sided unpaired t-test with Welsh correction. D Anchorage-dependent colony growth potential of MDA-MB-231 control and CIP2A K21A mutant clones. E Quantification of (D). Shown is mean of two technical replicates from each indicated cell line (n = 2). F Anchorage-independent colony growth potential of MDA-MB-231 control and CIP2A K21A mutant clones on soft agar. G Quantification of (F). Shown in mean +/− S.E.M of three technical replicates from each indicated cell line. Two-tailed t-test with Welsh correction. H Growth curves of orthotopic mammary fat pad xenograft tumours from MDA-MB-231 control (n = 7 mice) or CIP2A K21A mutant clones (n = 8 mice). Error bar represent mean +/− S.E.M. Two-sided Anova. I Numbers of detectable tumours and their mean volumes at day 30 from (H). J Western blot analysis of cleaved PARP (Cl.PARP), phosphorylated MEK and phosphorylated Vimentin from two independent MDA-MB-231 CIP2A K21A mutant clones cultured either on normal plastic or on low-attachment polyHEMA coated plates. Source data are provided as a Source Data file. K Schematic presentation how K21A mutation on CIP2A leads to protein destabilization and thereby releases B56 from CIP2A-mediated inhibition. This results in dephosphorylation of PP2A-B56 targets and in inhibition of tumorigenesis.
Fig. 3 Single amino acid mutation on the N-terminal head domain of CIP2A abrogates TNBC tumorigenicity. A Western blot analysis of CIP2A and MYC protein expression in two independent MDA-MB-231 CIP2A K21A mutant clones. Source data are provided as a Source Data file. B Proximity ligation assay (PLA) for interaction between HA-B56α and endogenous CIP2A. MDA-MB-231-Control and MDA-MB-231_K21A mutant clone1 cells transfected with HA-B56α construct were subjected to PLA with anti-HA and anti-CIP2A antibodies. Red dot indicates the association between HA-B56α and endogenous CIP2A proteins. Shown is a representative image from N = 3 PLA experiments. Scale bar = 10 µm. C Quantification of PLA shown in (B) using automated macro detecting PLA signals. Error bar represent mean +/− SD from 3 different fields from 2 technical replicates. Two-sided unpaired t-test with Welsh correction. D Anchorage-dependent colony growth potential of MDA-MB-231 control and CIP2A K21A mutant clones. E Quantification of (D). Shown is mean of two technical replicates from each indicated cell line (n = 2). F Anchorage-independent colony growth potential of MDA-MB-231 control and CIP2A K21A mutant clones on soft agar. G Quantification of (F). Shown in mean +/− S.E.M of three technical replicates from each indicated cell line. Two-tailed t-test with Welsh correction. H Growth curves of orthotopic mammary fat pad xenograft tumours from MDA-MB-231 control (n = 7 mice) or CIP2A K21A mutant clones (n = 8 mice). Error bar represent mean +/− S.E.M. Two-sided Anova. I Numbers of detectable tumours and their mean volumes at day 30 from (H). J Western blot analysis of cleaved PARP (Cl.PARP), phosphorylated MEK and phosphorylated Vimentin from two independent MDA-MB-231 CIP2A K21A mutant clones cultured either on normal plastic or on low-attachment polyHEMA coated plates. Source data are provided as a Source Data file. K Schematic presentation how K21A mutation on CIP2A leads to protein destabilization and thereby releases B56 from CIP2A-mediated inhibition. This results in dephosphorylation of PP2A-B56 targets and in inhibition of tumorigenesis.CC BY · PubMed Central
Fig. 4 CIP2A displaces PP2A-A from PP2A-B56α trimer and interacts directly with PP2Ac. A B56α sites identified in inter-molecular cross-links with CIP2A overlap with B56α contact sites with the scaffolding A subunit (PDB: 6NTS). A subunit is yellow, catalytic subunit is grey, and B56α is wheat. The XL-MS cross-links between CIP2A and B56α are in red. PP2A-A and PP2Ac interaction sites with B56α are shown in magenta, and light purple, respectively (based on refs. 40,41). The overlap between PP2A-A and CIP2A in B56α surface is indicated as transparent oval shape in the right panel. B Coomassie stained SDS-PAGE of PP2A trimer components interacting with CIP2A(1-560) after incubation with the pre-assembled PP2A-B56α heterotrimer (A-B56α-PP2Ac). A = PP2A-A; C = PP2Ac. Representative image from four experiments is shown. C Western blot analysis of the similar experiment as in (B). The different intensities of the Western blot signals between PP2A-A (A), B56α, and PP2Ac in the input (and between B56α, and PP2Ac in the eluates), is due to differential affinities of the antibodies used simultaneously to blot the membranes. N = 3 biological repeats. D GST pull-down assay for PP2A trimer-GST-CIP2A(1-560) interaction. Equal molar amounts of PP2A proteins were used in all the samples. The amount of CIP2A(1-560) protein was titrated against PP2A as indicated. The positions of molecular weight markers are unavailable. E, F Size-exclusion chromatography analysis of protein complexes between GST (F) or GST-CIP2A(1-560) (G) and either pre-assembled PP2A-A-B56α-PP2Ac trimer (ABC) (middle panels) or B56α and PP2Ac (B + C) proteins (lower panels). Proteins eluting from the indicated fractions were analyzed by Western blotting. Approximate molecular weights of protein complexes eluting from each fraction are based on calibration with standard proteins. The positions of molecular weight markers are unavailable. N = 1. G Schematic presentation of CIP2A mediated hijack of the PP2A-B56α complex. In normal cells with low CIP2A expression, the PP2A-B56α holoenzyme (A-B56α-C) remains intact. In cancer with high CIP2A expression CIP2A interacts directly with both B56α and PP2Ac resulting in expel of A-subunit from the trimer. Thus, in cancer cells CIP2A functions as a pseudo-A-subunit stabilizing the trimeric CIP2A-B56α-PP2Ac complex.
Fig. 4 CIP2A displaces PP2A-A from PP2A-B56α trimer and interacts directly with PP2Ac. A B56α sites identified in inter-molecular cross-links with CIP2A overlap with B56α contact sites with the scaffolding A subunit (PDB: 6NTS). A subunit is yellow, catalytic subunit is grey, and B56α is wheat. The XL-MS cross-links between CIP2A and B56α are in red. PP2A-A and PP2Ac interaction sites with B56α are shown in magenta, and light purple, respectively (based on refs. 40,41). The overlap between PP2A-A and CIP2A in B56α surface is indicated as transparent oval shape in the right panel. B Coomassie stained SDS-PAGE of PP2A trimer components interacting with CIP2A(1-560) after incubation with the pre-assembled PP2A-B56α heterotrimer (A-B56α-PP2Ac). A = PP2A-A; C = PP2Ac. Representative image from four experiments is shown. C Western blot analysis of the similar experiment as in (B). The different intensities of the Western blot signals between PP2A-A (A), B56α, and PP2Ac in the input (and between B56α, and PP2Ac in the eluates), is due to differential affinities of the antibodies used simultaneously to blot the membranes. N = 3 biological repeats. D GST pull-down assay for PP2A trimer-GST-CIP2A(1-560) interaction. Equal molar amounts of PP2A proteins were used in all the samples. The amount of CIP2A(1-560) protein was titrated against PP2A as indicated. The positions of molecular weight markers are unavailable. E, F Size-exclusion chromatography analysis of protein complexes between GST (F) or GST-CIP2A(1-560) (G) and either pre-assembled PP2A-A-B56α-PP2Ac trimer (ABC) (middle panels) or B56α and PP2Ac (B + C) proteins (lower panels). Proteins eluting from the indicated fractions were analyzed by Western blotting. Approximate molecular weights of protein complexes eluting from each fraction are based on calibration with standard proteins. The positions of molecular weight markers are unavailable. N = 1. G Schematic presentation of CIP2A mediated hijack of the PP2A-B56α complex. In normal cells with low CIP2A expression, the PP2A-B56α holoenzyme (A-B56α-C) remains intact. In cancer with high CIP2A expression CIP2A interacts directly with both B56α and PP2Ac resulting in expel of A-subunit from the trimer. Thus, in cancer cells CIP2A functions as a pseudo-A-subunit stabilizing the trimeric CIP2A-B56α-PP2Ac complex.CC BY · PubMed Central
Fig. 5 CIP2A mutes LxxIxE-motif substrate binding of B56α. A Sites of CIP2A-B56α cross-links (in red; PDB: 6NTS) mapped in relation to indicated LxxIxE-binding groove of B56α. Residues indicated in light purple constitutes the LxxIxE-binding region of B56α between amino acids 212-271. Residues in dark purple indicate amino acids involved in PP2A-A interaction as explained in Fig. 4. B CIP2A(1-560)V5 out-competes prototypical LxxIxE motif target BubR1(LxxIxE peptide 647-720) from its direct association with B56α. Source data are provided as a Source Data file. C Quantification of GST pull-down data from (B) shown as a mean + S.E.M from N = 3 biological repeats. Two-sided t-test. D B56α competition assay using GST-BubR1(647-720) alone, or in combination with CIP2A N-terminal head peptide (aa. 18-40). Source data are provided as a Source Data file. E Quantification for data from D shown as a mean + S.E.M from N = 4 biological repeats. Two-sided t-test. F In vitro binding assay using purified recombinant GST-tagged CIP2A(1-560) and B56α WT or B56 variants Y215Q and R222E, which contain mutations that prevent interaction with LxxIxE groove substrate proteins10. Source data are provided as a Source Data file. G Quantification of data from (F) shown as mean + S.E.M from N = 3 biological repeats. H GFP-tagged B56α WT or indicated triple mutant were expressed in HEK-293-T cells. The amount of PP2A-A subunit bound to GFP-tagged B56α upon GFP trap pull-down was quantified by anti-PP2A-A immunoblotting. Shown are the mean values + S.E.M of the ratios of the quantified anti-PP2A-A signal versus the quantified anti-GFP signal, relative to the B56α WT (set at 100 %) from N = 3 biological replicates. A two-sided one-sample t-test. I Triple B56α mutant (K181A/K217A/K227A) exhibits loss of K227 (B56)-D117(PP2A-A) salt bridge. Overlay of PP2A-B56α (PDBID 6NTS: PP2A-A, yellow; B56α, beige) and PP2A-B56γ (PDBID 2IAE: PP2A-a, light cyan, B56γ, cyan), with PP2A-A D177 and B56α/B56γ K227/K202 residues shown as sticks and labelled. H-bond interactions are shown using dotted lines. Image was generated using Pymol.
Fig. 5 CIP2A mutes LxxIxE-motif substrate binding of B56α. A Sites of CIP2A-B56α cross-links (in red; PDB: 6NTS) mapped in relation to indicated LxxIxE-binding groove of B56α. Residues indicated in light purple constitutes the LxxIxE-binding region of B56α between amino acids 212-271. Residues in dark purple indicate amino acids involved in PP2A-A interaction as explained in Fig. 4. B CIP2A(1-560)V5 out-competes prototypical LxxIxE motif target BubR1(LxxIxE peptide 647-720) from its direct association with B56α. Source data are provided as a Source Data file. C Quantification of GST pull-down data from (B) shown as a mean + S.E.M from N = 3 biological repeats. Two-sided t-test. D B56α competition assay using GST-BubR1(647-720) alone, or in combination with CIP2A N-terminal head peptide (aa. 18-40). Source data are provided as a Source Data file. E Quantification for data from D shown as a mean + S.E.M from N = 4 biological repeats. Two-sided t-test. F In vitro binding assay using purified recombinant GST-tagged CIP2A(1-560) and B56α WT or B56 variants Y215Q and R222E, which contain mutations that prevent interaction with LxxIxE groove substrate proteins10. Source data are provided as a Source Data file. G Quantification of data from (F) shown as mean + S.E.M from N = 3 biological repeats. H GFP-tagged B56α WT or indicated triple mutant were expressed in HEK-293-T cells. The amount of PP2A-A subunit bound to GFP-tagged B56α upon GFP trap pull-down was quantified by anti-PP2A-A immunoblotting. Shown are the mean values + S.E.M of the ratios of the quantified anti-PP2A-A signal versus the quantified anti-GFP signal, relative to the B56α WT (set at 100 %) from N = 3 biological replicates. A two-sided one-sample t-test. I Triple B56α mutant (K181A/K217A/K227A) exhibits loss of K227 (B56)-D117(PP2A-A) salt bridge. Overlay of PP2A-B56α (PDBID 6NTS: PP2A-A, yellow; B56α, beige) and PP2A-B56γ (PDBID 2IAE: PP2A-a, light cyan, B56γ, cyan), with PP2A-A D177 and B56α/B56γ K227/K202 residues shown as sticks and labelled. H-bond interactions are shown using dotted lines. Image was generated using Pymol.CC BY · PubMed Central
Fig. 6 Validation of hijack and mute model of B56α inhibition by CIP2A in cellulo. A NIH3T3 cells, stably expressing human CIP2A(1-905) V5, or empty vector control (see Supplementary Fig. 8D), were transiently transfected with YFP-B56α WT, followed by immunoprecipitation using GFPTrap and analysis by mass spectrometry. B Proteins differentially interacting with B56α in CIP2A(1-905)V5 over-expressing cells (N = 3) vs. control (N = 3). Indicated proteins exceed the threshold of 2-fold difference with p < 0.05 (two-sided t-test using log2 of protein abundances, normalized to the protein abundance of B56α in the CTRL_1 sample, as an input). C Pie-chart of share of proteins displaying either decreased or increased binding to B56α upon CIP2A over-expression (excluding PPP2R1A and CIP2A). Bar graph indicates percentual share of proteins with putative LxxIxE motif among the proteins which interaction with B56α was decreased by CIP2A. D Pie-chart presentation of percentual share of proteins dephosphorylated (FDR < 0.05) in CIP2A K21A clone1 as compared to control clone in relation to putative LxxIxE motif found from the dephosphorylated protein (in orange), or whether dephosphorylated protein is an interactor of a protein with validated LxxIxE motif (in red). E Significantly enriched kinase motifs based on phosphopeptides dephosphorylated in CIP2A K21A clone1. Background indicates the number of motifs found from all phosphopeptides identified by MS from the same samples. F Reactome analysis image capture of the process Senescence enriched in targets dephosphorylated in CIP2A K21A clone1 as compared to control clone. Schematic presentation of CIP2A-mediated PP2A-B56α inhibition by the identified hijack and mute mechanism. In normal cells with low CIP2A expression, PP2A-B56α binds to its substrate protein (light blue) via LxxIxE groove and the adjacent acidic patch (orange) resulting in substrate dephosphorylation. In cancer cells with high CIP2A gene transcription, CIP2A binding to PP2A-B56α trimer results in expel of A and the formation of CIP2A-B56α-PP2Ac trimer. In this alternative trimer CIP2A shields the LxxIxE groove and the adjacent acidic patch from B56α substrates and thereby the substrate remains phosphorylated (dark blue). Binding of CIP2A to B56α via its head domain further stabilizes CIP2A protein.
Fig. 6 Validation of hijack and mute model of B56α inhibition by CIP2A in cellulo. A NIH3T3 cells, stably expressing human CIP2A(1-905) V5, or empty vector control (see Supplementary Fig. 8D), were transiently transfected with YFP-B56α WT, followed by immunoprecipitation using GFPTrap and analysis by mass spectrometry. B Proteins differentially interacting with B56α in CIP2A(1-905)V5 over-expressing cells (N = 3) vs. control (N = 3). Indicated proteins exceed the threshold of 2-fold difference with p < 0.05 (two-sided t-test using log2 of protein abundances, normalized to the protein abundance of B56α in the CTRL_1 sample, as an input). C Pie-chart of share of proteins displaying either decreased or increased binding to B56α upon CIP2A over-expression (excluding PPP2R1A and CIP2A). Bar graph indicates percentual share of proteins with putative LxxIxE motif among the proteins which interaction with B56α was decreased by CIP2A. D Pie-chart presentation of percentual share of proteins dephosphorylated (FDR < 0.05) in CIP2A K21A clone1 as compared to control clone in relation to putative LxxIxE motif found from the dephosphorylated protein (in orange), or whether dephosphorylated protein is an interactor of a protein with validated LxxIxE motif (in red). E Significantly enriched kinase motifs based on phosphopeptides dephosphorylated in CIP2A K21A clone1. Background indicates the number of motifs found from all phosphopeptides identified by MS from the same samples. F Reactome analysis image capture of the process Senescence enriched in targets dephosphorylated in CIP2A K21A clone1 as compared to control clone. Schematic presentation of CIP2A-mediated PP2A-B56α inhibition by the identified hijack and mute mechanism. In normal cells with low CIP2A expression, PP2A-B56α binds to its substrate protein (light blue) via LxxIxE groove and the adjacent acidic patch (orange) resulting in substrate dephosphorylation. In cancer cells with high CIP2A gene transcription, CIP2A binding to PP2A-B56α trimer results in expel of A and the formation of CIP2A-B56α-PP2Ac trimer. In this alternative trimer CIP2A shields the LxxIxE groove and the adjacent acidic patch from B56α substrates and thereby the substrate remains phosphorylated (dark blue). Binding of CIP2A to B56α via its head domain further stabilizes CIP2A protein.CC BY · PubMed Central

Verification

Claims the paper makes

37 Valid · 1 Not valid · 7 Not checked · 140 Own results and interpretations

117 more claims · 18 with their cited sources checked

Create a free account to see all 185 claims and to verify the 1 reference still open.

See all claims — free account
  • Probably not a substantial claim. 43
  • It may state two separate claims as one. 25

Create a free account to see these claims.

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

Each contradiction between two passages listed here was confirmed by an independent check.

2 of 2

Citations

Cites

Show all 65 references

Cited by

See all 36

Metadata

Authors
Pavic, K., Gupta, N., Omella, J. D., Derua, R., Aakula, A., Huhtaniemi, R., Määttä, J. A., Höfflin, N., Okkeri, J., Wang, Z., Kauko, O., Varjus, R., Honkanen, H., Abankwa, D., Köhn, M., Hytönen, V. P., Xu, W., Nilsson, J., Page, R., Janssens, V., Leitner, A., & Westermarck, J.
Affiliations
  • Åbo Akademi University (FI)
  • KU Leuven (BE)
  • Tampere University (FI)
  • University of Freiburg (DE)
  • ShanghaiTech University (CN)
  • University of Luxembourg (LU)
  • University of Copenhagen (DK)
  • University of Arizona (US)
  • ETH Zurich (CH)
Corresponding author
Westermarck, Jukka
Venue
Nature Communications
Published
2023-02-28
Volume
14
Issue
1
Pages
1143-1143
ISSN
2041-1723 (ISSN-L)
OpenAlex
W4322588601
Cited by
36
References
65
Citations by year
2026: 7 · 2025: 10 · 2024: 11 · 2023: 8
FWCI
3.19
Type
journal article
Language
en
Open access
Licence
Locations
  • Nature Communications (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • Research at the University of Copenhagen (University of Copenhagen) (publishedVersion, cc-by)
  • Lirias (KU Leuven) (submittedVersion, cc-by)
  • Open Repository and Bibliography (University of Luxembourg) (submittedVersion, other-oa)
  • RePEc: Research Papers in Economics (submittedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
  • Åbo Akademi University Research Portal (submittedVersion, cc-by)
  • Tampere University Institutional Repository (Tampere University) (submittedVersion, cc-by)
  • Repository for Publications and Research Data (ETH Zurich) (submittedVersion, cc-by)
  • ETH Zürich Research Collection
Funders
  • Suomen Kulttuurirahasto
  • K. Albin Johanssons Stiftelse
  • Jane ja Aatos Erkon Säätiö
  • U.S. Department of Health & Human Services | NIH | National Institute of General Medical Sciences (R01GM144483)
  • Academy of Finland (331237)
  • Sigrid Juséliuksen Säätiö
  • Finnish Cancer Foundations
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Tyrosine Phosphatases
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Kinase Regulation and GTPase Signaling
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Signaling Pathways in Disease
Keywords
CIP2A, protein phosphatase 2A, oncogenicity, substrate binding pocket, protein stability, MYC expression, MEK phosphorylation, triple-negative breast cancer, protein complex structure
MeSH terms
Amino Acids, Autoantigens, Humans, Membrane Proteins, Phosphorylation, Protein Processing, Post-Translational, Catalytic Domain, Intracellular Signaling Peptides and Proteins, Protein Phosphatase 2, Carcinogenesis, Triple Negative Breast Neoplasms

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Structural mechanism for inhibition of PP2A-B56α and oncogenicity by CIP2A. https://app.cochat.ai/papers/10.1038/s41467-023-36693-9
The paper
Pavic, K., Gupta, N., Omella, J. D., Derua, R., Aakula, A., Huhtaniemi, R., Määttä, J. A., Höfflin, N., Okkeri, J., Wang, Z., Kauko, O., Varjus, R., Honkanen, H., Abankwa, D., Köhn, M., Hytönen, V. P., Xu, W., Nilsson, J., Page, R., . . . Westermarck, J. (2023). Structural mechanism for inhibition of PP2A-B56α and oncogenicity by CIP2A. Nature Communications. https://doi.org/10.1038/s41467-023-36693-9

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.